Benchmarking Maintenance Therapy Survival in First-Line Platinum-Based Chemotherapy-Treated Patients with Advanced Urothelial Carcinoma Using Simulated Disease Modeling.

Galsky, Matthew D; Wirtz, Heidi S; Bloudek, Brian; Hepp, Zsolt; Farrar, Mallory; Timmons, Jack; Lenero, Enrique; Powles, Thomas

Galsky, Matthew D; Wirtz, Heidi S; Bloudek, Brian; Hepp, Zsolt; Farrar, Mallory; Timmons, Jack; Lenero, Enrique; Powles, Thomas.

Afiliação

Galsky MD; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Wirtz HS; Seagen Inc., Bothell, WA, USA.
Bloudek B; Curta Inc., Seattle, WA, USA.
Hepp Z; Seagen Inc., Bothell, WA, USA.
Farrar M; Seagen Inc., Bothell, WA, USA.
Timmons J; Curta Inc., Seattle, WA, USA.
Lenero E; Astellas Pharma Inc., Northbrook, IL, USA.
Powles T; Barts Cancer Centre, Queen Mary University of London, London, UK.

Clin Epidemiol ; 15: 765-773, 2023.

Article em En | MEDLINE | ID: mdl-37366420

Palavras-chave

maintenance avelumab; maintenance eligibility; oncology simulation model; overall survival; urothelial carcinoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Epidemiol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google